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Purpose: Sufentanil is a μ-opioid agonist with a
high therapeutic index in preclinical studies and no
active metabolites, and it is highly lipophilic, thereby
enabling a transmucosal route of administration.
Rapid distribution from the plasma after IV sufentanil
administration results in a short duration of action
requiring excessive repeated dosing if used for post-
operative analgesia. The sufentanil sublingual tablet
system (SSTS) is a handheld, preprogrammed, patient-
controlled analgesia system designed to allow patients
to self-administer sufentanil 15-μg tablets under their
tongue with a 20-minute lockout. The pharmacoki-
netic (PK) characteristics of sufentanil, administered
by different routes of delivery and after single and
repeated sublingual (SL) administration, were exam-
ined in 2 studies.
Methods: A randomized, open-label, crossover
study in healthy subjects evaluated the PK proﬁle of
sufentanil 15 μg administered by different routes: IV,
SL, buccal (BU), and PO. A second open-label, cross-
over study in healthy subjects evaluated the PK
parameters after single and repeated doses (full SSTS
drug cartridge of 40 consecutive SL doses adminis-
tered every 20 minutes) of a sufentanil 15-μg SL
tablet. Doses were self-administered using the SSTS.
Findings: In the route of administration study (n ¼
25), mean Cmax values were highest with IV admin-
istration, and bioavailability values were: SL, 59%;
BU, 78%; and PO, 9%. The absorption across the
oral mucosa was associated with a median plasma
half-time (time from Cmax to 50% of Cmax) that was
25-fold longer (2.5 hours) with SL versus IV admin-
istration (0.1 hours). In the single- and repeated-dose
study (n ¼ 38), mean AUC0–1 was 125.5 h  pg/mL,
and Cmax was 35.0 pg/mL, with a median Tmax of*Consultant, AcelRx Pharmaceuticals.
January 20150.8 hours after the administration of a single sufenta-
nil SL tablet. With 40 consecutive doses, Cmax was 8-
fold higher compared with that of a single dose, and
steady state was achieved after the 13th dose. Median
plasma half-time after the 40th dose was not statisti-
cally longer than that after a single dose (2.7 vs 2.2
hours, respectively), and the median Tmax was 0.3
hours after the last repeated dose.
Implications: These study results support the via-
bility of the SSTS for use in patient-controlled anal-
gesia. The wide range of mean drug concentrations
achieved after repeated dosing at 20-minute intervals
compared with those with a single dose suggests the
ﬂexibility of patient-controlled dosing to meet indi-
vidual analgesic requirements. The prolonged plasma
half-time with SL administration is expected to pro-
vide a more appropriate duration of analgesia com-
pared with that of IV administration, and the PK
properties of repeated-dose administration support a
20-minute lockout interval. (Clin Ther. 2015;37:145–
155) & 2015 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: context-sensitive half-time, patient-
controlled analgesia, sublingual, sufentanil.INTRODUCTION
Despite increased awareness and the availability of
guidelines and quality standards encouraging or man-
dating improvements in acute pain management,1–3
the majority of surgical patients receive inadequate
postoperative pain relief.4–7 Although results have& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
145
Clinical Therapeuticsdiffered slightly between studies, a signiﬁcant proportion
of hospitalized patients experience moderate to severe
pain after surgery. In a survey of 250 surgical patients,
80% experienced acute postoperative pain, and of
these, the pain was moderate or severe in 86%.4
Another study among surgical inpatients reported that
41% experienced moderate to severe pain on the 1st
postoperative day, and that 15% continued to
experience this level of pain on the 4th postoperative
day.7 Poor postoperative pain control may delay
recovery and negatively affect morbidity and
mortality.8,9 These ﬁndings suggest a crucial need
for innovative approaches to acute pain management
that will result in improved analgesic efﬁcacy with a
lower risk for adverse events (AEs) and complications
from therapy.
IV patient-controlled analgesia (PCA) provides an
effective method for postoperative pain control.10,11
However, despite its beneﬁts, IV PCA has drawbacks,
such as the risks for device-programming errors,
medication-prescribing errors, pump malfunction, lim-
itations on patient mobility, poor IV access, infection
at the venipuncture site, and challenges with setting up
and maintaining a functioning infusion pump.12–14
Furthermore, morphine and hydromorphone, which
are the opioids most commonly used for IV PCA, are
associated with a potential risk for delayed AEs
because both drugs have less-than-ideal pharmacoki-
netic (PK)/pharmacodynamic properties for use in IV
PCA.15–17 Opioids function at CNS receptors and not
in the plasma; thus, conventional venous PK param-
eters can be misleading in determining opioid effects.
Thus, the plasma/CNS equilibration half-life (t1/2ke0)
is more accurate than is Tmax in predicting onset of
action.14,18,19 Morphine, its active metabolite mor-
phine-6-glucuronide, and hydromorphone exhibit
prolonged plasma:CNS equilibration times (t1/2ke0,
approximately 3 hours, 6 hours, and 46 minutes,
respectively) compared with more lipophilic μ-opioid
agonists, such as sufentanil and fentanyl (t1/2ke0,
6 minutes).16,17,20
An ideal PCA opioid would provide a rapid and
consistent onset of action afforded by fast equilibration
within the CNS and would have limited efﬂux trans-
porter effects, no active metabolites, limited effect of
hepatic or renal impairment on clearance, and an
acceptable tolerability proﬁle. An ideal PCA delivery
system would provide noninvasive drug delivery with-
out restricting mobility and would eliminate errors in146medication prescribing and device programming.14
Sufentanil is a μ-opioid agonist that is rapidly equili-
brating with the CNS, has a high therapeutic index and
no active metabolites, and thus has the potential to
reduce the risks and enhance the pain control associ-
ated with PCA.14,21 However, the use of sufentanil for
IV PCA is limited by a very short initial distribution
half-life (1.4 minutes) when administered by the IV
route.22 Pilot studies suggest that a sufentanil
sublingual tablet system (SSTS) provides a highly
consistent PK proﬁle with a rapid uptake and onset
of action while minimizing the high peak levels and
short duration associated with IV administration, and
also avoids the ﬁrst-pass metabolism associated with
the PO route of administration.23 Results from 2 PK
studies in healthy volunteers are presented here,
including: (1) the favorable PK proﬁle of sublingual
(SL) administration relative to IV and PO
administration; and (2) the PK proﬁle of sufentanil SL
tablets after single- and repeated-dose administration.
SUBJECTS AND METHODS
For each study, the study protocol, amendments, and
informed-consent form were approved by MidLands
Independent Institutional Review Board (Overland
Park, Kansas). All subjects provided written informed
consent before study participation, and each subject
was free to withdraw from the study for any reason at
any time. Both studies were conducted in compliance
with the principles of the Declaration of Helsinki and
the International Conference on Harmonisation
Guidelines for Good Clinical Practice. The studies
were conducted during July 2012 and February 2013.
Subject Selection
For each study, nonsmoking, healthy men and
women aged 18 to 45 years with a body mass index
between 18 and 30 kg/m2 were eligible if they had no
clinically signiﬁcant medical conditions as determined
by the investigator and had a negative urine test for
drugs of abuse, cotinine, and alcohol at screening.
Women were required to agree to use a medically
acceptable form of contraception during the study.
Subjects were excluded if they had a resting heart
rate of o40 or 4100 beats/min; a corrected (Frider-
icia) QT interval Z450 msec and/or a history of risk
factors for torsades de pointes; systolic blood pressure
outside of the range of 90 to 139 mm Hg and/or
diastolic blood pressure outside of the range of 60 toVolume 37 Number 1
S.K. Willsie et al.89 mm Hg; orthostatic hypotension or symptoms of
lightheadedness, dizziness, or fainting on standing;
hemoglobin o13.5 g/dL (in men) or o11.5 g/dL (in
women); positive blood test for HIV antibody, hep-
atitis B surface antigen, and/or hepatitis C antibody;
allergy or hypersensitivity to opioids and/or naltrex-
one; recent (within 3 to 14 days of dosing) use of
prescription or over-the-counter medications; and/or
consumption of caffeine 4450 mg/d.
Study Design
Route of Administration Study
In this single-center, randomized, open-label, 4-
treatment, 4-period, 6-sequence crossover study, each
subject received a single IV dose of sufentanil,*
followed by 3 different routes of administration of
sufentanil sublingual tablets dosed by a health care
professional using forceps and according to 1 of 6
randomly assigned sequences. The 4 routes of
administration were slow IV push over 1 minute, SL
administration, buccal (BU) administration (in front of
lower front teeth to avoid accidental swallowing), and
PO. The following sequences of treatment were used:
sequence 1: IV, SL, BU, PO; sequence 2: IV, SL, PO,
BU; sequence 3: IV, BU, SL, PO; sequence 4: IV, BU,
PO, SL; sequence 5: IV, PO, SL, BU; and sequence 6:
IV, PO, BU, SL.
Single- and Repeated-Dose Study
This single-center, open-label, ﬁxed-sequence cross-
over study was conducted in healthy subjects. Each
subject received a single sufentanil 15-μg SL tablet,
followed later by 40 consecutive doses administered
every 20 minutes. Doses were self-administered by
each subject under the direction of the site staff using
the SSTS, a handheld, preprogrammed, patient-
administered analgesia device with a 20-minute lock-
out interval that is under review by the US Food and
Drug Administration for the treatment of moderate to
severe acute pain in the hospital setting.
In both studies, subjects remained in the facility
during all treatments. A 48-hour washout period
separated each treatment period. The washout period
began with the start of dosing. Subjects received
naltrexone 50 mg PO both before and after dosing
with sufentanil tablets to block the μ-opioid effects of*Trademark: Sufentas (Taylor Pharmaceuticals, Decatur, Illi-
nois [now defunct]).
January 2015sufentanil. Aside from naltrexone, the only concurrent
medications allowed during the study were oral
contraceptives, acetaminophen (o2 g/d), and multi-
vitamins. Subjects were asked to discontinue the
intake of caffeine, alcohol, xanthines, grapefruits (or
juice), Seville oranges (orange marmalade), and qui-
nine 4 days before study drug administration.
Study Assessments
For both studies, a complete medical history,
physical examination, clinical laboratory tests (blood
chemistry, complete blood count, urinalysis, and
serology), 12-lead ECG, pregnancy test, and alcohol,
cotinine, and drug screen were performed at screening.
The physical examination, clinical laboratory tests,
and ECG were repeated at the end of the study. Blood
pressure, heart rate, respiratory rate, and oxygen
saturation were determined at screening and on each
study day. Tolerability monitoring included periodic
measurement of vital signs and other assessments
of AEs.
Pharmacokinetic Assessments
Standard PK parameters were calculated, and
results across routes of administration were com-
pared. The PK parameters determined from plasma
sufentanil concentrations were Cmax and Tmax, both of
which were determined directly from observations.
AUC was calculated using the linear trapezoidal
method for AUC0–t and AUC0–1. AUC0–1 was
calculated as the sum of AUC0–t and Clast/ke, where
Clast was the last measurable concentration and ke was
the apparent terminal elimination rate constant (esti-
mated from the slope of the elimination phase of the
concentration–time curve). The geometric mean of
AUC0–τ (based on the redosing interval [τ] of 20
minutes) after the last (40th) repeated dose was
calculated and divided by the geometric mean
AUC0–20 for the single dose to determine the accumu-
lation ratio. The t1/2 value was calculated as ln2/ke.
The clearance (CL) in each subject was calculated as
dose/AUC0–1 for IV sufentanil only. In each subject,
estimates of the absolute amount of sufentanil ab-
sorbed were calculated by multiplying each treat-
ment’s AUC0–1 and CL derived from IV sufentanil.
The bioavailability of each treatment was calculated
as the ratio of the amount of sufentanil absorbed
divided by the nominal dose administered. Plasma
half-time (HT) was measured as the time from Tmax to147
Clinical Therapeuticstime at which plasma concentration reached half of
Cmax after discontinuation of drug administration.
In the route of administration study, blood samples
from IV treatment for PK analysis were obtained
predose and at 1, 4, 7, 10, 15, 20, 30, 45, 60, 90,
120, 180, 240, 360, 480, 600, 720, and 840 minutes
and at 24 hours after dosing. For the SL, BU, and PO
routes, blood samples for PK analysis were obtained
predose and at 10, 20, 30, 40, 50, 60, 70, 80, 90, 120,
180, 240, 360, 480, 600, 720, and 840 minutes and at
24 hours after dosing.
For the PK analysis of single-dose sufentanil, blood
samples were obtained predose and at 5, 10, 15, 20,
30, 40, 50, 60, 70, 80, 90, 120, 180, 240, 360, 480,
600, 720, 800, and 840 minutes and at 24 hours after
dosing. For the PK analysis of repeated-dose sufenta-
nil, blood samples were obtained pre-dose and at 20,
120, 240, 360, 480, 600, 720, 760, 780, 785, 790,
795, 800, 810, 820, 830, 840, 850, 860, 870, 900,
960, 1020, 1140, 1260, 1380, 1500, 1580, and 1620
minutes and at 37 hours after the administration of
the ﬁrst dose on day 3.
Analytical Methods
Plasma concentrations of sufentanil were deter-
mined by PRA Health Sciences (Lenexa, Kansas) using
a validated HPLC-MS/MS method. The HPLC system
(Acquity; Waters Corporation, Milford, Massachu-
setts) was coupled to an API 5500 MS/MS detector
(AB Sciex, Farmington, Massachusetts). Chromato-
graphic separation was achieved on a Zorbax 300-
SCX HPLC column (50  3.0 mm; internal diameter,
5 mm; Agilent Technologies, Inc, Santa Clara, Cal-
ifornia). The mobile phase consisted of 80% acetoni-
trile/20% ammonium formate buffer (vol/vol) that
was delivered at a ﬂow rate of 1.0 mL/min. Brieﬂy,
sufentanil standard solutions were diluted in methanol
and diluted in blank plasma to provide concentrations
of 1.00, 2.00, 5.00, 20.0, 50.0, 200, 500, 800, and
1000 pg/mL. Subsequently, 50.0 μL of internal stand-
ard solution was added to the mixture, and liquid–
liquid extraction was performed. The supernatants
were evaporated at 451C and reconstituted in 150 μL
of the mobile phase solution. This was followed by a
10-μL injection of the sample into the HPLC-MS/MS
system. The calibration standards were prepared in
bulk in plasma and were extracted along with blanks,
plasma, and quality-control samples. Calibration curves
were linear over the range of 1.00 to 1000 pg/mL,148and the R2 values were always40.99. The lower limit
of quantiﬁcation (LLOQ) was 1.00 pg/mL. At each
concentration, the overall bias was within 15.0% of
the nominal value (20.0% at the LLOQ) and the
within-run, between-run, and total %CVs were all
r15.0% (20.0% at the LLOQ).Data Analysis
Descriptive statistics (eg, mean [SD], least squares
[LS] geometric mean [for natural logarithm (nl)-trans-
formed ANOVA model analysis], LS means [for non-
transformed ANOVA model analysis], geometric
means for nl-transformed paired t test analysis, and
90% CI) of the PK parameters were calculated. All
statistical tests were 2-sided and a signiﬁcance level of
0.05 was used. All statistical analyses were performed
using SAS version 9.1 (SAS Institute Inc, Cary, North
Carolina).Route of Administration Study
An ANOVA model for crossover design was
performed on nl-transformed AUC0–t, AUC0–1, and
Cmax values. This ANOVA model included sequence,
subject within sequence, period, treatment, and period
by treatment interaction factors. This same ANOVA
model for crossover design was used to analyze Tmax,
ke, t1/2, and plasma HT without log-transformation.
The CL and absolute amount of sufentanil absorbed
are summarized descriptively.Single- and Repeated-Dose Study
Individual subject treatment-speciﬁc PK parameters
(AUC0–1, AUC0–20, and Cmax) were nl-transformed
ﬁrst. The Tmax, ke, t1/2, and plasma HT were not log-
transformed. A paired t test was used to test the
signiﬁcance of the mean difference in these PK
parameters against 0. Assessment of steady state for
the sufentanil 15-μg SL tablet after multiple dosing
was performed using the Helmert method.24 This
method of determining steady state evaluates the
ratio of the LS geometric mean of the drug concen-
tration at each corresponding time point, divided by
the LS geometric mean of the pooled concentrations of
all remaining time points. The assessment time with a
calculated ratio that does not statistically differentiate
from a value of 1 is considered the time to steady
state.Volume 37 Number 1
S.K. Willsie et al.RESULTS
Subject Disposition and Baseline Demographic
Characteristics
Route of Administration Study
In the route of administration study, 25 subjects
were enrolled and included in the tolerability analysis,
and 22 were included in PK analysis. Three subjects
withdrew consent during the study. Baseline demo-
graphic characteristics were comparable among
groups according to treatment sequence (Table I).
Single- and Repeated-Dose Study
For the single- and repeated-dose study, 40 subjects
were enrolled and included in the tolerability analysis, and
38 were included in the PK analysis. One subject was dis-
continued due to noncompliance, and 1 was discontinued
due to an AE of mild nausea. At baseline, the mean (SD)
age was 28.0 (6.0) years, 21 (52.5%) were male, mean
(SD) weight was 75.0 (11.4) kg, and mean (SD) body
mass index was 25.9 (3.1) kg/m2. Twenty-two (55.0%)
were black or African American, 17 (42.5%) were white,
and 1 (2.5%) was of "other" race (data not shown).
Pharmacokinetic Properties
Route of Administration Study
For the comparison of routes of administration, relative
to IV administration, the bioavailability values of SL, BU,
and PO sufentanil treatments were 59%, 78%, and 9%,
respectively, and IV sufentanil CL was 57.6 (14.0) L/h. The
other PK parameters are shown in Table II. ComparedTable I. Baseline demographic characteristics of the sub
of sufentanil 15 μg administered by different ro
Characteristic
Treatmen
1 (n ¼ 4) 2 (n ¼ 4) 3 (n ¼ 4)
Age, mean (SD), y 27.0 (5.7) 29.0 (6.6) 21.0 (1.8)
Male, no. (%) 2 (50) 1 (25) 1 (25)
Race, no. (%)
Black/African
American
3 (75) 2 (50) 2 (50)
White 1 (25) 1 (25) 1 (25)
Other/Asian 0 1 (25) 1 (25)
BMI, kg/m2 22.9 (2.6) 24.8 (3.3) 21.1 (3.6)
BMI ¼ body mass index.
January 2015with IV administration, SL and BU administration was
associated with lower exposure (AUC) and lower Cmax
(Figure 1). The mean AUC0–1 and Cmax values with PO
administration were lower by 85% and 89%, respectively,
compared with those with SL administration. The median
plasma HT values were 2.5, 2.3, and 2.0 hours,
respectively, with SL, BU, and PO administration, which
were signiﬁcantly longer than that with IV administration
(0.1 hours).Single- and Repeated-Dose Study
In the single- and repeated-dose study, after a single
dose of sufentanil 15-μg SL tablet, mean Cmax was 35.0
pg/mL, and median Tmax was 0.8 hours (Table III).
Repeated administration of sufentanil 15-μg SL tablet
every 20 minutes for 40 consecutive doses was asso-
ciated with greater overall systemic exposure (Cmax and
AUC0–1) versus that of a single dose. The mean Cmax
with repeated dosing was 8-fold higher than after a
single dose (276.0 vs 35.0 pg/mL, respectively), and
median Tmax was 12.0 hours (Table III and Figure 2).
Css after repeated dosing of sufentanil 15-μg SL tablets
was achieved by dose number 13 (ie, by 4 hours).
After the last (40th) repeated dose, Cmax was 7-fold
greater compared with that after single-dose admin-
istration (P o 0.001) (Table III and Figure 3). The
accumulation ratio (ratio of geometric means of
AUC0–20,last dose over AUC0–20,single dose) was 26.6.
After the last repeated dose, median Tmax,last dose was
0.3 hours, consistent with having obtained steadyjects in the study of the pharmacokinetic properties
utes.
t Sequence
All Subjects
(n ¼ 25)4 (n ¼ 5) 5 (n ¼ 4) 6 (n ¼ 4)
36.6 (7.3) 29.5 (4.1) 33.8 (9.4) 29.8 (7.7)
4 (80) 3 (75) 2 (50) 13 (52)
0 1 (25) 4 (100) 12 (48)
5 (100) 3 (75) 0 11 (44)
0 0 0 2 (8)
26.7 (2.1) 24.9 (3.0) 25.5 (2.7) 24.4 (3.2)
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Table II. Pharmacokinetic properties of single-dose administration of sufentanil 15 μg, by route of
administration.
Parameter SL (n ¼ 22) IV (n ¼ 22) BU (n ¼ 22) PO (n ¼ 22)* P†
AUC0–1, h  pg/mL o0.001
Mean (SD) 163.4 (52.5) 273.8 (61.1) 212.5 (57.0) 24.9 (14.1)
LSGM (90% CI) 156.0 (138.4–175.9) 270.4 (239.8–304.9) 206.4 (183.1–232.8) 22.4 (19.7–25.5)
Cmax, pg/mL o0.001
Mean (SD) 40.6 (14.8) 445.1 (312.0) 58.9 (25.7) 4.3 (3.8)
LSGM (90% CI) 38.5 (30.9–47.9) 365.0 (292.9–454.9) 53.5 (43.4–66.7) 3.3 (2.6–4.1)
Tmax, h 0.010
Mean (SD) 0.9 (0.3) 0.1 (0.0) 1.1 (0.5) 1.2 (0.5)
Median 0.8 0.1 0.9 1.1
LSM (90% CI) 0.9 (0.8–1.0) 0.1 (–0.1–0.2) 1.1 (0.9–1.2) 1.2 (1.1–1.3)
t1/2, h NS
Mean (SD) 9.7 (7.3) 11.3 (7.6) 9.4 (7.7) 6.2 (6.6)
Median 7.2 10.5 5.3 4.4
LSM (90% CI) 9.6 (6.9–12.4) 11.4 (8.6–14.1) 9.4 (6.7–12.2) 6.6 (3.5–9.7)
Plasma HT, h NS
Mean (SD) 2.6 (0.9) 0.2 (0.1) 2.1 (1.1) 2.2 (1.0)
Median 2.5 0.1 2.3 2.0
LSM (90% CI) 2.6 (2.3–2.9) 0.2 (-0.1–0.5) 2.1 (1.8–2.4) 2.3 (1.9–2.7)
BU ¼ buccal; HT ¼ half-time; time from Cmax to 50% Cmax; LSGM ¼ least squares geometric mean; LSM ¼ least squares
mean; SL ¼ sublingual.
*For the PO treatment, AUC0–1, n ¼ 18; t1/2, n ¼ 18; and plasma HT, n ¼ 16.
†P for the overall comparison among all treatments was based on type III analysis from the ANOVA model that included
sequence, period, treatment, and period by treatment ﬁxed factors, and subject within sequence random factor.
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Figure 1. Plasma concentrations over time after a single 15-μg dose of sufentanil via the IV, sublingual (SL),
buccal (BU), and PO routes.
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Table III. Pharmacokinetic properties of single- and repeated-dose sufentanil 15-μg sublingual tablets.
Parameter Single Dose (n ¼ 38) Repeated Dose (n ¼ 38) P*
AUC0–1, h  pg/mL o0.001
Mean (SD) 125.5 (47.7) 4216.6 (1225.5)
GM (90% CI) 117.9 (106.7–130.3) 4064.3 (3751.8–4402.8)
Cmax, pg/mL o0.001
Mean (SD) 35.0 (12.2) 276.0 (77.3)
GM (90% CI) 33.1 (30.0–36.2) 265.1 (247.2–287.2)
Tmax, h o0.001
Mean (SD) 0.9 (0.1) 10.9 (0.5)
Median (90% CI) 0.8 (0.76–0.94) 12.0 (10.1–11.7)
GM ¼ geometric mean.
These repeated-dose data are from the entire dosing period in contrast to the data in Table IV which is all from after the last
of the repeated doses.
*P for the test of the mean change between treatments was based on the paired t test.
S.K. Willsie et al.state by 4 hours with a 20-minute redosing interval
(Table IV). Mean t1/2 was increased after the last dose
of repeated administration compared with that of a
single dose. Median plasma HT was not signiﬁcantlyM
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Figure 2. Plasma concentrations over time with the adm
15-μg sublingual tablets. Repeated doses were
13 hours.
January 2015different after a single dose versus the 40th dose,
suggesting a predictable and consistent offset after
maximal repeated dosing of sufentanil 15-μg SL tablet
over 13 hours.15 µg Single Dose     
15 µg Multiple Doses
 Dose (min)
20 840 960 1080 1200 1320 1440
inistration of single- and repeated-dose sufentanil
self-administered by patients every 20 minutes for
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Figure 3. Plasma concentrations over time for single versus last (40th) dose of sufentanil 15-μg sublingual tablets.
Clinical TherapeuticsTolerability Analysis
Route of Administration Study
The subjects' concurrently receiving naltrexone
during both studies was a confounding factor forTable IV. Pharmacokinetic properties of single- and rep
sufentanil 15-μg sublingual tablets.
Parameter Single Dose (n ¼ 38)
AUC0–1, h  pg/mL
Mean (SD) 3.2 (1.8)
GM (90% CI) 2.7 (2.3–3.2)
Cmax, pg/mL
Mean (SD) 35.0 (12.2)
GM (90% CI) 33.1 (30.0–36.2)
Tmax, h
Mean (SD) 0.9 (0.3)
Median (90% CI) 0.8 (0.8–0.9)
t1/2, h
Mean (SD) 6.6 (6.7)
Median (90% CI) 4.2 (4.7–8.4)
Plasma HT, h
Mean (SD) 2.2 (0.9)
Median (90% CI) 2.2 (1.9–2.4)
GM ¼ geometric mean; HT ¼ (half-time), the time from Cmax t
*P for the test of the mean change between treatments was bas
152assessing the tolerability of sufentanil. In the route of
administration study, 8 subjects reported 12 AEs
during treatment with IV sufentanil (4 reports of
nausea [2 related to study drug], 2 of headacheeated-dose (after the last dose) administration of
Last Repeated Dose (n ¼ 38) P*
o0.001
75.1 (22.4)
71.5 (66.0–78.3)
o0.001
249.6 (72.1)
239.9 (219.2–259.8)
o0.001
0.4 (0.2)
0.3 (0.3–0.4)
o0.001
17.6 (18.9)
12.7 (12.4–22.8)
NS
2.5 (0.6)
2.7 (2.3–2.7)
o 50% Cmax.
ed on the paired t test.
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S.K. Willsie et al.[1 related], and 1 each of photophobia, abdominal
pain [related], infusion-site pain, decreased appetite,
ﬂat affect [related], and hyperhidrosis); 4 subjects
reported 5 AEs during treatment with SL administra-
tion (1 report for each of oral paresthesia [related],
fatigue [related], headache [related], paresthesia, and
ﬂat affect [related]); 5 subjects reported 5 AEs during
treatment with BU administration (2 reports of head-
ache and 1 each of nausea, hypoesthesia oral [related],
and ﬂat affect [related]); and 3 subjects reported
5 AEs during treatment with PO administration
(2 reports of nausea [both related] and 1 each of
diarrhea, vomiting, and dizziness). All AEs were
considered by the investigators as mild in intensity,
1 AE required treatment, and all events resolved by
the end of the study. No clinically signiﬁcant ﬁndings
on clinical laboratory testing, physical examination
including vital sign measurements, or ECG were
observed.
Single- and Repeated-Dose Study
In the single- and repeated-dosing study, 5 subjects
(12.5%) reported 7 AEs with single-dose administra-
tion and 18 subjects (46.2%) reported 37 AEs with
repeated-dose administration. One AE occurred in
45% of subjects with single-dose sufentanil: head-
ache (4 [10.0%; 2 related]). The AEs occurring in
45% of subjects with repeated-dose sufentanil were
nausea (6 [15.4%; all related]), headache (6 [15.4%;
5 related]), somnolence (4 [10.3%; all related]),
dizziness (3 [7.7%; all related]), hot ﬂush (3 [7.7%;
all related]), and photophobia (2 [5.1%; both re-
lated]). All AEs were rated as mild by the investigators
with the exception of one related AE of somnolence,
which was rated as moderate in severity. No clinically
signiﬁcant ﬁndings on clinical laboratory testing,
physical examination including vital sign measure-
ments, or ECG were observed.
DISCUSSION
In a comparison of routes of administration of sufenta-
nil, the systemic exposure, as measured by Cmax and
AUC0–1, was signiﬁcantly less and Tmax was longer
with SL administration compared with IV administra-
tion. The plasma HT of SL administration was 25-fold
longer than that of IV administration, and this is
consistent with the dosing observed in patients using
SSTS in the Phase III clinical trials. In a study in patients
treated for up to 72 hours after major abdominalJanuary 2015surgery and major joint replacement surgery, patients
received treatment with SSTS approximately every 80
minutes, on average and demonstrated signiﬁcantly
greater analgesia.14 Patients and healthcare providers
rated SSTS as superior to IV PCA with morphine for the
global assessment of method of pain control. Sufentanil
has not been utilized clinically for IV PCA due to its
short plasma HT; the SL route of administration of
sufentanil ameliorates this issue.
Sufentanil is metabolized by hepatic cytochrome P-450
3A4 when administered IV25; however, this enzyme is
also present in the small intestine and can substantially
reduce bioavailability after PO (swallowed) administra-
tion of drugs that are cytochrome P-450 3A4 sub-
strates.26 Therefore, very low (o10%) bioavailability of
a swallowed sufentanil tablet is expected. BU adminis-
tration of the tablet was associated with a slightly greater
bioavailability, most likely due to the placement in front
of the lower front teeth, which is a protected location that
minimizes the swallowing of saliva containing solubilized
sufentanil. Clinically, this oral location is not convenient
for patients to dose using the device, but it was chosen to
avoid accidental swallowing of the very small tablet for
this PK study.
The PK results with single and repeated adminis-
tration of sufentanil 15-μg SL tablets were consistent
with those from previous studies of sufentanil SL
tablets.23 As expected, both Cmax and AUC were
greater after repeated administrations compared with
those after single-dose administration of sufentanil.
However, Cmax with repeated SL administration of
the 15-μg sufentanil tablet at maximal frequency of
dosing (every 20 minutes) was lower than that after a
single IV dose of sufentanil 15 μg. This ﬁnding suggests
a greater margin of tolerability with the sufentanil SL
tablet compared with IV sufentanil dosing with respect
to avoiding rapid high plasma concentrations that may
produce undesirable AEs, such as chest rigidity (3% -
9% occurrence rate) and postoperative respiratory
depression (less than 1% occurrence rate).27 Even
with repeated dosing at the maximum frequency of
administration, the full SSTS drug cartridge of 40 doses
of sufentanil SL tablets was associated with mean
plasma concentrations that remained approximately
at or below the median plasma sufentanil concentra-
tion (250 pg/mL) required for patients to breathe on
their own after anesthesia with sufentanil.28 Studies of
the clinical use of the SSTS in postoperative patients
have reported dosing frequencies and plasma sufentanil153
Clinical Therapeuticsconcentrations much lower than the maximal
utilization evaluated in this Phase I study.14,29,30
The Tmax of 20 minutes after repeated SL doses of
sufentanil supports the results of an earlier, shorter-
duration study that reported a median Tmax of 20
minutes (mean, 24 minutes) after the last (4th)
repeated dose of SL sufentanil.23 In addition, the
rapid t1/2ke0 of 6 minutes for sufentanil suggests that
the plasma Tmax is a relevant indicator of peak CNS
drug effect.20 The rapid equilibration of sufentanil is
likely due to its high lipophilicity (octanol:buffer
partition coefﬁcient, 1757:1) as well as a 20% non-
ionized fraction (at pH 7.4).31 Morphine is not
lipophilic (octanol:buffer partition coefﬁcient, 1:1)
and, therefore, even when delivered intravenously,
has a t1/2ke0 of 2.8 hours and the active metabolite,
morphine-6-glucuronide, has an even more delayed
equilibration (t1/2ke0, 6.4 hours), in which case the
CNS opioid effects of morphine signiﬁcantly lag
behind the plasma concentrations.16,18,19
Despite an increase in the elimination half-life with
repeated SL dosing, no signiﬁcant prolongation in
plasma HT was observed, suggesting that redosing every
20 minutes allows for a predictable and consistent offset
of analgesic effect with sufentanil SL tablets even with a
maximal dosing frequency of over 13 hours. The high
accumulation ratio may be expected given that the
lockout interval of 20 minutes is much shorter than the
elimination half-life of sufentanil (164 minutes).22
Clinically, patients utilizing PCA modalities dose to
effect, and the interdosing interval is longer than the
lockout interval, as reported in the Phase III SSTS
studies.14,29,30 Achievement of steady state at as early as
4 hours with maximal repeated dosing also may be
expected given the highly lipophilic nature of sufen-
tanil, in which case the AUC associated with the terminal
log-linear portion is small relative to the total area under
the entire plasma drug–concentration proﬁle. Therefore,
the achievement of the steady-state trough concentration
is minimally affected by the terminal half-life. A limi-
tation of the study relates to the assessment of AEs, since
naltrexone was administered orally to block the phar-
macodynamic effects of sufentanil.CONCLUSIONS
The ﬁndings from these 2 studies support the viability
of the 15-μg SSTS for use in PCA with a 20-minute
lockout period. The sufentanil SL tablet dispensed154from a handheld system potentially offers the attrib-
utes of an ideal PCA system, that is, it provides for a
rapid and consistent onset of action, allows patients to
self-dose with a 20-minute lockout, and provides a
noninvasive drug-delivery method without restricting
mobility. These ﬁndings, together with those from
previously published clinical studies of the SSTS,
support its efﬁcacy and tolerability in treating patients
with acute postoperative pain.
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